MicroTC: Impact of Severe Brain Injury on Neuro-vascular and Endothelial Regulation of Peripheral Microcirculation.

Sponsor
University Hospital, Grenoble (Other)
Overall Status
Recruiting
CT.gov ID
NCT04597879
Collaborator
(none)
30
1
8
3.8

Study Details

Study Description

Brief Summary

Severe brain injury (SBI) is one of the world's leading causes of death and disability in young adults, but its peripheral vascular consequences in humans are poorly understood.

This prospective, monocentric, pathophysiological study aims to investigate differences in vasoreactivity in the anterior aspect of the contralateral forearm at the most injured cerebral hemisphere between patients with severe head trauma and patients with severe trauma without associated brain injury matched on sex and age (+/- 5 years).

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Severe brain injury (SBI) is one of the world's leading causes of death and disability in young adults.

    Its impact on cerebral vascularization is well known. At the systemic level, it induces transient dysfunctions that can develop into severe failures, even in cases of isolated SBI. Studies on a mouse model of SBI show alterations in peripheral vascular reactivity that persist over time and are linked to endothelial dysfunction, the mechanism of which is a decoupling of endothelial NO synthase in a context of systemic inflammation. However, no data are available regarding the peripheral vascular consequences of SBI in humans.

    The main objective of this prospective, monocentric, pathophysiological study is to determine whether the postocclusive hyperaemic response at the anterior surface of the contralateral forearm to the most injured cerebral hemisphere differs between patients with severe brain injury and patients with severe trauma without associated head injury matched on sex and age (+/- 5 years), by studying the amplitude of post-occlusive hyperaemia (maximum amplitude expressed as percentage of vasodilatation and area under the curve : AUC) as a function of the group.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    30 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Prospective
    Official Title:
    Study of the Impact of Severe Brain Injury on the Neuro-vascular and Endothelial Regulation of Peripheral Microcirculation.
    Actual Study Start Date :
    Aug 1, 2021
    Actual Primary Completion Date :
    Aug 15, 2021
    Anticipated Study Completion Date :
    Mar 31, 2022

    Arms and Interventions

    Arm Intervention/Treatment
    Severe traumatic brain injury

    Severe trauma without brain trauma

    Healthy controls

    Outcome Measures

    Primary Outcome Measures

    1. Post-occlusive hyperaemia [0-60 days]

      Maximum amplitude expressed as percentage of vasodilation and area under the curve: AUC

    Secondary Outcome Measures

    1. Post-occlusive hyperaemia with local anesthesia [0-60 days]

      Maximum amplitude expressed as percentage of vasodilation and area under the curve: AUC

    2. Current-Induced Hyperaemia [0-60 days]

      Area under the curve expressed as a percentage of the baseline.

    3. Current-Induced Hyperaemia with local anesthesia [0-60 days]

      Area under the curve expressed as a percentage of the baseline.

    4. Local thermal hyperaemia [0-60 days]

      Maximum amplitude of the initial peak expressed as a percentage of the baseline and area under the curve of the delayed plateau.

    5. Local thermal hyperaemia with local anesthesia [0-60 days]

      Maximum amplitude of the initial peak expressed as a percentage of the baseline and area under the curve of the delayed plateau.

    6. Flow amplitude after local cooling [0-60 days]

      Amplitude of initial vasoconstriction averaged over 1 min around the lowest flow value during the first 5 minutes.

    7. Transient venous post-compression hyperaemia [0-60 days]

      Area under the curve and percentage change from baseline.

    8. Study of vasoreactivity in patients with severe brain injury [0-60 days]

      Extent of post-occlusive hyperaemia, current-induced hyperaemia, thermal hyperaemia and cold response in patients with severe brain injury.

    9. Study of vasoreactivity in healthy subjects [Study visit]

      Description of the magnitude of post-occlusive hyperaemia, current-induced hyperaemia, thermal hyperaemia and cold response in healthy subjects.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    Healthy volunteers :
    • Men and women, over 18 years of age

    • Affiliation to a social security scheme

    • Signed Consent

    Patients with Severe Brain Injury :
    • Male and female, over 18 years of age

    • Isolated severe brain injury, defined by an initial Glasgow score less than or equal to 8.

    • Affiliation to a social security scheme

    • Signed informed consent

    Severe traumatized patients without associated severe brain injury:
    • men and women, over 18 years of age

    • severe trauma, defined by an Injury Severity Score (ISS) ≥ 16.

    • absence of associated severe brain injury, defined by an initial Glasgow score less than or equal to 8.

    • affiliation to or beneficiary of a social security scheme

    • signed informed consent

    Exclusion Criteria:
    • Hypersensitivity to lidocaine and/or prilocaine or to amide type local anesthetics or to any of the excipients of the cream.

    • History of axillary lymph node dissection, trauma or axillary surgery

    • Prohibited treatments and procedures :

    • In patients with head trauma: ongoing treatment with systemic vasodilators (calcium channel blocker, milrinone).

    • In healthy volunteers: no treatment will be authorized other than paracetamol, hormone supplementation (contraceptive pill, hormone therapy, thyroid hormones).

    • Pregnant, parturient or breastfeeding women

    • Subject in a period of exclusion from another study,

    • Person deprived of liberty by judicial or administrative decision, person subject to a legal protection measure,

    • Subject having exceeded the annual compensation threshold for testing

    • Subject cannot be contacted in case of emergency

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University Hospital Grenoble France 38700

    Sponsors and Collaborators

    • University Hospital, Grenoble

    Investigators

    • Principal Investigator: Jean-Luc Cracowksi, Pr, University Hospital, Grenoble

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University Hospital, Grenoble
    ClinicalTrials.gov Identifier:
    NCT04597879
    Other Study ID Numbers:
    • 2020-A00183-36
    • 38RC20.014
    First Posted:
    Oct 22, 2020
    Last Update Posted:
    Sep 14, 2021
    Last Verified:
    Sep 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by University Hospital, Grenoble
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 14, 2021